

## Special Issue

# Mechanisms and Novel Therapeutic Approaches for Colorectal Cancer

### Message from the Guest Editor

Since the 1970s, the molecular biological and biochemical mechanisms of the pathogenesis of colon adenocarcinomas have been studied to provide a better understanding of colorectal cancer. Many studies have been particularly valuable in understanding and elucidating the mechanisms involved in the development of malignancy in detail. Although several genetic factors involved in the initiation, promotion, progression, and metastasis of colorectal cancer have recently been well established, the field of colorectal cancer treatment still has several unmet medical needs. This has also enabled early detection of precancerous lesions and expanded appropriate diagnosis so as to make possible the further development of effective treatments. At this point, we recognize the need to organize information from the past and a common understanding of emerging technologies. This Special Issue will consider various treatment options in non-clinical fields based on information on the mechanism, pathogenesis, diagnosis, and prognosis of colorectal cancer.

### Guest Editor

Dr. Keun-Yeong Jeong

The Research Center, PearlInMires Co., Ltd., Seoul 07292, Republic of Korea

### Deadline for manuscript submissions

closed (30 September 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/179856](https://mdpi.com/si/179856)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).